• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

    11/11/24 5:01:32 PM ET
    $DECA
    $SCLX
    Blank Checks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DECA alert in real time by email

    NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $15,063.74 to fund the one-month extension from November 11, 2024, to December 11, 2024. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex's discretion, into the Company's Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $119,772.04 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.

    About the Company

    Denali Capital Acquisition Corp. is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.

    Forward-Looking Statements

    This press release includes forward looking statements that involve risks and uncertainties. Forward-looking statements are subject to numerous conditions, risks and changes in circumstances, many of which are beyond the control of the Company, including those set forth in the "Risk Factors" section of the Company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.



    Contact:
    646-978-3133
    Get the next $DECA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DECA
    $SCLX

    CompanyDatePrice TargetRatingAnalyst
    Scilex Holding Company
    $SCLX
    1/27/2025$22.00Buy
    D. Boral Capital
    Scilex Holding Company
    $SCLX
    10/16/2024$14.00Buy
    Alliance Global Partners
    Scilex Holding Company
    $SCLX
    6/13/2024$13.00Buy
    Rodman & Renshaw
    Scilex Holding Company
    $SCLX
    10/16/2023$4.00Buy
    B. Riley Securities
    Scilex Holding Company
    $SCLX
    10/13/2023$4.00Buy
    B. Riley Securities
    Scilex Holding Company
    $SCLX
    10/9/2023$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $DECA
    $SCLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Shah Jaisim bought $13,800 worth of shares (30,000 units at $0.46), increasing direct ownership by 27% to 139,333 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      12/18/24 7:04:41 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Executive Chairperson Ji Henry bought $8,351 worth of shares (8,888 units at $0.94), increasing direct ownership by 3% to 320,161 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/31/24 12:44:57 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Shah Jaisim bought $31,670 worth of shares (32,000 units at $0.99), increasing direct ownership by 41% to 109,333 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      10/29/24 6:59:31 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    $SCLX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Scilex Holding Company

      SCHEDULE 13G/A - Scilex Holding Co (0001820190) (Subject)

      5/8/25 4:15:17 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Scilex Holding Company

      POS AM - Scilex Holding Co (0001820190) (Filer)

      5/7/25 5:30:11 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Scilex Holding Company

      POS AM - Scilex Holding Co (0001820190) (Filer)

      5/7/25 5:24:45 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    $SCLX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

      NEW YORK, NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) --  Denali Capital Acquisition Corp. (NASDAQ:DECA) (the "Company") announced today that it has deposited into the Company's trust account (the "Trust Account") an aggregate of $874.78 to fund the one-month extension from May 11, 2025 to June 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (NASDAQ:SCLX, "Scilex")), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company's initial business combination or the date of the liquidation of the Company. Upon the closing of a business

      5/9/25 4:00:00 PM ET
      $DECA
      $SCLX
      Blank Checks
      Finance
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.

      PALO ALTO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced an upcoming presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicia

      5/1/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule

      PALO ALTO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it has received notification from The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company was required to maintain a minimum closing bid price of $1.00 per share for at least ten consecutive trading days.

      4/30/25 1:46:47 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    $SCLX
    Financials

    Live finance-specific insights

    See more
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

      PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of April 11, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be May 2, 2025 (the "New Record Date"). Subject

      4/22/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025

      PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the "Dividend") to its stockholders and certain other securityholders of Scilex. The new record

      3/10/25 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

      US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any shares of the Dividend Stock (including any such shares held by brokerage firms) may not be sold, transferred or otherwise disposed of.Scilex's transfer agent, Continental Stock Transfer & Trust Company, has been notified of the lock-up extension to April 14, 2025. PALO ALTO, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain manag

      1/31/25 9:00:00 AM ET
      $SCLX
      $SRNE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch

    $DECA
    $SCLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 3,250,000 shares, decreasing direct ownership by 6% to 51,039,214 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/23/25 7:49:49 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 779,371 shares, decreasing direct ownership by 1% to 54,289,214 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/17/25 8:27:54 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Sclx Stock Acquisition Jv Llc disposed of 5,000,000 shares, decreasing direct ownership by 8% to 55,068,585 units (SEC Form 4)

      4 - Scilex Holding Co (0001820190) (Issuer)

      1/6/25 7:12:44 PM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    $SCLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Scilex Holding with a new price target

      D. Boral Capital initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $22.00

      1/27/25 8:08:33 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Scilex Holding with a new price target

      Alliance Global Partners initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $14.00

      10/16/24 8:01:57 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Scilex Holding with a new price target

      Rodman & Renshaw initiated coverage of Scilex Holding with a rating of Buy and set a new price target of $13.00

      6/13/24 7:16:15 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    $SCLX
    Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.

      PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has added to its Board of Directors a highly accomplished leader in interventional and multidisciplinary spine, musculoskeletal and orthopedic care, Annu Navani, M.D. Dr. Navani has served as the Chief Executive Officer of Comprehensive Spine and Sports Center since 2008, a leader in interventional and multidisciplinary spine, musculoskeletal, and orthopedic care. Over th

      7/23/24 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates

      PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the launch of its redesigned website showcasing the Company's growing portfolio of non-opioid pain management therapeutics. The new website can be accessed by visiting www.scilexholding.com, The features of the new and improved website include: Sleek, modern web design with dynamic elements and illustrations;An overview of the Company's science and expanded product portfolio and pr

      3/4/24 9:00:00 AM ET
      $SCLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DECA
    $SCLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      12/6/24 4:17:05 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 5:49:50 PM ET
      $DECA
      Blank Checks
      Finance
    • Amendment: SEC Form SC 13G/A filed by Denali Capital Acquisition Corp.

      SC 13G/A - Denali Capital Acquisition Corp. (0001913577) (Subject)

      11/14/24 2:35:09 PM ET
      $DECA
      Blank Checks
      Finance